DR3 Monoclonal Antibody (JD3), Biotin, eBioscience™, Invitrogen™

Description

• Description: The JD3 monoclonal antibody reacts with human DR3, also known as Apo-3, WSL-1, TRAMP, LARD, DDR3, and TR3
• DR3, a novel death receptor is expressed at low level by monocytes and granulocytes
• Interaction of DR3 with its ligand activates NF-kappa B pathway and induces apoptosis
• Initially, DR3 was thought to be a receptor for TWEAK, but further studies have shown that TWEAK could induce apoptosis via receptors distinct from DR3
• JD3 has been reported for use in flow cytometric analysis
• Applications Reported: The JD3 antibody has been reported for use in flow cytometric analysis
• Applications Tested: The JD3 antibody has been tested by flow cytometric analysis of human peripheral leukocytes and human DR3-transfected cells
• It is recommended that the reagent be carefully titrated for optimal performance in the assay of interest
• Filtration: 0.2 μm post-manufacturing filtered
• DR3/TNFRSF25 is a member of the TNF-receptor superfamily
• This receptor is expressed preferentially in the tissues enriched in lymphocytes, and it may play a role in regulating lymphocyte homeostasis
• This receptor has been shown to stimulate NF-kappa B activity and regulate cell apoptosis
• The signal transduction of this receptor is mediated by various death domain containing adaptor proteins
• Knockout studies in mice suggested the role of DR3/TNFRSF25 in the removal of self-reactive T cells in the thymus
• Multiple alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported, most of which are potentially secreted molecules
• The alternative splicing of this gene in B and T cells encounters a programmed change upon T-cell activation, which predominantly produces full-length, membrane bound isoforms, and is thought to be involved in controlling lymphocyte proliferation induced by T-cell activation.